Nagoya University researchers engineered next-generation CAR-T cells targeting Eva1 protein to enhance solid tumor immunotherapy. CIC bioGUNE elucidated molecular drivers of aggressive metastatic hormone-naïve prostate cancer, revealing unique transcriptional profiles. Advances in patient-derived xenograft models improve preclinical cancer research by preserving tumor heterogeneity, facilitating personalized co-clinical trials. Additionally, tumor-associated macrophages have been shown to promote breast cancer metastasis via lncRNA RP11-627G18.1, providing novel therapeutic targets.